PMID- 17591020
OWN - NLM
STAT- MEDLINE
DCOM- 20070806
LR  - 20181201
IS  - 1359-6535 (Print)
IS  - 1359-6535 (Linking)
VI  - 12
IP  - 3
DP  - 2007
TI  - Fate and function of hepatitis-C-virus-specific T-cells during 
      peginterferon-alpha2b therapy for acute hepatitis C.
PG  - 303-16
AB  - BACKGROUND: Strong hepatitis C virus (HCV)-specific T-cell responses are 
      associated with spontaneous clearance of acute hepatitis C. However, recent 
      studies described a decline in HCV-specific CD8+ T-cells during interferon 
      treatment, suggesting that the success of acute HCV therapy might be independent 
      of adaptive immunity. METHODS: T-cell responses of eight human leukocyte antigen 
      (HLA)-A2-positive, acutely infected patients treated with peginterferon-alpha2b 
      were studied by ELISPOT and proliferation assays and flow cytometry analysis 
      using HCV-specific tetramers. RESULTS: HCV-specific T-cells predominately 
      declined during therapy. However, diverse patterns of CD4+ and CD8+ T-cell 
      kinetics were observed. In patients with sustained virological response chemokine 
      receptor 3 (CXCR-3) expression of HCV-specific CD8+ T-cells was upregulated, 
      indicating homing to the liver. Low levels of T-cells remained detectable 
      throughout treatment and follow up. In contrast, T-cells of a relapse patient did 
      not upregulate CXCR-3 but displayed a higher staining for annexin-V, followed by 
      a complete loss of peripheral virus-specific CD8+ T-cells by week 12. 
      CONCLUSIONS: Kinetics of HCV-specific T-cell responses are heterogeneous in 
      interferon-treated patients with acute hepatitis C. The decline of T-cells might 
      be a consequence of both apoptosis and homing. The balance between cell death and 
      regulation of chemokine receptors might lead to different long-term outcomes.
FAU - Wiegand, Johannes
AU  - Wiegand J
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical 
      School, Germany.
FAU - Cornberg, Markus
AU  - Cornberg M
FAU - Aslan, Nuray
AU  - Aslan N
FAU - Schlaphoff, Verena
AU  - Schlaphoff V
FAU - Sarrazin, Christoph
AU  - Sarrazin C
FAU - Kubitschke, Anne
AU  - Kubitschke A
FAU - Buggisch, Peter
AU  - Buggisch P
FAU - Ciner, Ayse
AU  - Ciner A
FAU - Jaeckel, Elmar
AU  - Jaeckel E
FAU - Manns, Michael P
AU  - Manns MP
FAU - Wedemeyer, Heiner
AU  - Wedemeyer H
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Antivir Ther
JT  - Antiviral therapy
JID - 9815705
RN  - 0 (Annexin A5)
RN  - 0 (Antiviral Agents)
RN  - 0 (CXCR3 protein, human)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
RN  - 0 (Receptors, CXCR3)
RN  - 0 (Receptors, Chemokine)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - G8RGG88B68 (peginterferon alfa-2b)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Amino Acid Sequence
MH  - Annexin A5/metabolism
MH  - Antiviral Agents/*therapeutic use
MH  - Binding Sites/genetics/immunology
MH  - CD4-Positive T-Lymphocytes/immunology/metabolism
MH  - CD8-Positive T-Lymphocytes/immunology/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epitopes, T-Lymphocyte/genetics
MH  - Female
MH  - Flow Cytometry
MH  - HLA-A2 Antigen/immunology
MH  - Hepacivirus/genetics/*immunology
MH  - Hepatitis C/*drug therapy/immunology/virology
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*therapeutic use
MH  - Lymphocyte Count
MH  - Male
MH  - Molecular Sequence Data
MH  - Polyethylene Glycols
MH  - RNA, Viral/blood
MH  - Receptors, CXCR3
MH  - Receptors, Chemokine/metabolism
MH  - Recombinant Proteins
MH  - Species Specificity
MH  - Treatment Outcome
EDAT- 2007/06/27 09:00
MHDA- 2007/08/07 09:00
CRDT- 2007/06/27 09:00
PHST- 2007/06/27 09:00 [pubmed]
PHST- 2007/08/07 09:00 [medline]
PHST- 2007/06/27 09:00 [entrez]
PST - ppublish
SO  - Antivir Ther. 2007;12(3):303-16.